Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
ALK Gene Mutation: early-phase trial registry
1 of 3 indexed ALK Gene Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
ALK Gene Mutation: 3 US clinical trials tracked, 1 recruiting.
ALK Gene Mutation is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Southern California, running 1 of these trials.
Enrollment posture brief
Registry condition alk-gene-mutation
OPEN 1 | RECR 33% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
ALK Gene Mutation lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for ALK Gene Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
ALK Gene Mutation is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
University of Colorado, Denver
NCT03042221
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
University of Virginia
NCT05370469
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
University of Southern California
NCT03049618
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on ALK Gene Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on ALK Gene Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this ALK Gene Mutation page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 ALK Gene Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Southern California sponsors the most ALK Gene Mutation trials on record, review their full trial history before evaluating a specific study. See University of Southern California's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ALK Gene Mutation condition card totals 3 registered trials; most-linked intervention Fitbit Sense; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.